Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients  by Kalantar-Zadeh, Kamyar et al.
Kidney International, Vol. 63 (2003), pp. 793–808
PERSPECTIVES IN RENAL MEDICINE
Reverse epidemiology of cardiovascular risk factors in
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hypocholesterolemia, or hypocreatininemia, are known riskReverse epidemiology of cardiovascular risk factors in mainte-
factors of poor outcome in dialysis patients. The existence ofnance dialysis patients. Conventional risk factors of cardiovas-
reverse epidemiology may have a bearing on the managementcular disease and mortality in the general population such as
of dialysis patients. It is possible that new standards or goalsbody mass, serum cholesterol, and blood pressure are also
for such traditional risk factors as body mass, serum cholesterol,found to relate to outcome in maintenance dialysis patients,
but often in an opposite direction. Obesity, hypercholesterol- and blood pressure should be considered for these individuals.
emia, and hypertension appear to be protective features that
are associated with a greater survival among dialysis patients.
A similar protective role has been described for high serum
Patients with end-stage renal disease (ESRD) whosecreatinine and possibly homocysteine levels in end-stage renal
life prolongation is dependent on maintenance dialysis ex-disease (ESRD) patients. These findings are in contrast to
the well-known association between over-nutrition and poor perience much poorer outcome as compared to the general
outcome in the general population. The association between population [1–3]. Numerous reports indicate that in con-
under-nutrition and adverse cardiovascular outcome in dialysis
trast to the general population, where markers of over-patients, which stands in contrast to that seen in non-ESRD
nutrition are associated with increased risk of cardiovas-individuals, has been referred to as “reverse epidemiology.”
Publication bias may have handicapped or delayed additional cular disease, decreased nutritional measures, such as a
reports with such paradoxical findings in ESRD patients. The low body mass index (BMI) or weight-for-height [4] or
etiology of this inverse association between conventional risk a reduced serum cholesterol or creatinine concentrationfactors and clinical outcome in dialysis patients is not clear.
[5], are strongly correlated with increased morbidity andSeveral possible causes are hypothesized. First, survival bias
mortality, including a higher risk of cardiovascular eventsmay play a role since only a small number of patients with
chronic kidney disease (CKD) survive long enough to reach and death in dialysis patients (Fig. 1). Similar findings
ESRD. Hence, the dialysis patients are probably a distinctively have been reported concerning blood pressure in that
selected population out of CKD patients and may not represent
low blood pressure, and not hypertension, appears to bethe risk factor constellations of their CKD predecessors. Sec-
more strongly related to poor outcome in dialysis patientsond, the time discrepancy between competitive risk factors
may play a role. For example, the survival disadvantages of (Table 1). These paradoxic observations have been re-
under-nutrition, which is frequently present in dialysis patients, ferred to as “reverse epidemiology” [6, 7] or “risk factor
may have a major impact on mortality in a shorter period of paradox” [8–10]. Such terminologies may not necessarilytime, and this overwhelms the long-term negative effects of
mean that the principles of vascular pathophysiology areover-nutrition on survival. Third, the presence of the “malnutri-
different in ESRD patients but may indicate that theretion-inflammation complex syndrome” (MICS) in dialysis pa-
tients may also explain the existence of reverse epidemiology are other superimposed and more dominant factors that
in dialysis patients. Both protein-energy malnutrition and in- cause apparent reversal of the relationships between risk
flammation or the combination of the two are much more factors and outcome. The phenomenon of an establishedcommon in dialysis patients than in the general population
risk factor in the general population having a markedlyand many elements of MICS, such as low weight-for-height,
different and indeed opposite predictive pattern in ESRD
may not be unique to the dialysis population. Elderly
Key words: ESRD, dialysis, reverse epidemiology, risk factor paradox,
individuals in nursing homes [11], hospitalized patientscardiovascular risk factors, malnutrition-inflammation complex syn-
drome. [12], patients with malignancy [13], and possibly other
subpopulations may have similar epidemiology. Hence,
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cept in Asian Americans [22]. BMI predicts mortality
risk in dialysis patients independently of serum albumin
and recorded clinical assessment of nutritional status.
The Diaphane Collaborative Study Group in France was
one of the first to report that overall mortality risk de-
creased with increasing BMI [23]. Notably, however, this
was reported for a cohort of younger, mostly nondiabetic,
French patients treated with hemodialysis during the
1970s, and adjustment was only made for age and sex.
Leavy et al [20] described the predictive value for mortal-
ity over 5 years of follow-up of a number of risk factors,
recorded at baseline, in a national sample of 3607 hemo-
dialysis patients in the 1990s. In hazard regression mod-
els, low BMI was independently and significantly pre-
dictive of increased mortality; its independent predictive
value of mortality risk persisted even 5 years later. No
evidence of increasing mortality risk was found for higher
values of BMI. Fleischmann et al [21] analyzed the BMI
Fig. 1. Reverse epidemiology of mortality risk factors in maintenance
and its relation to 1-year mortality and hospital stay indialysis patients. Comparison between the impacts of body mass index
(BMI) on all-cause mortality in the general population versus the main- 1346 predominately African American hemodialysis pa-
tenance hemodialysis population. The general population data are tients. The 1-year survival rate was significantly higher in
adopted from Calle et al, N Engl J Med 341:1097-1105, 1991 (combined
the overweight patients and lower in the underweightmen and women, healthy, nonsmoker) [136]. The hemodialysis data
are adopted from Leavey et al, Nephrol Dial Transplant 16:2386-2394, patients. With a one-unit increase in BMI over 27.5 kg/m2,
2001 (combined data from the United States and Europe) [26]. *Each the relative risk for dying was reduced by 30% (P 
population has a different follow-up period: 14 years for the general
0.04), and with a one-unit decrease in BMI below 20,population versus 4 years for hemodialysis patients. **BMI stratifica-
tions are different in two populations: X-axis is based on the original the relative risk was increased by 1.6-fold (P  0.01).
graph of the general population and the original hemodialysis BMI The longer the patients were on dialysis, the lower were
subgroup ranges are printed additionally along the hemodialysis curve.
the BMI values. The greater duration of dialysis vintage
with lower BMI might be a cause of the increased mortal-
ity, but it is unlikely that slightly higher dialysis vintage
with lower BMI could have accounted for such a substan-ELEMENTS OF REVERSE EPIDEMIOLOGY
tial impact on mortality [21]. Wolfe et al [24] investigatedWeight and body mass: Is obesity protective?
the role of body size on 2-year mortality risk associated
The mean body weight in the general population in the with dialysis dose in 9165 hemodialysis patients and
United States is on the rise [14]. An appreciable number of found that body size markers, including body weight
epidemiologic studies have shown a strong relationship and BMI, were independently and inversely related to
between obesity and increased risk of cardiovascular dis- mortality when adjusted for age and diabetes as well as
ease and mortality in the general population [15–17]. for Kt/V. Another recent study by Port et al [25], based
BMI, also known as the Quetelet index [i.e., ratio of weight on data from 45,967 incident hemodialysis patients after
(kg) to height squared (m2)] [18], and other adjusted adjustment for demographics and 18 comorbid conditions,
measures of weight (such as for height) [4] are the com- found that of the three body-size groups, the lowest BMI
monly used parameters to quantify changes in body mass group had a 42% higher mortality risk than the highest
adjusted for height, and the association between body BMI tertile. Kopple et al [3] evaluated approximately
mass and outcome. In some studies of normal adults, a 13,000 hemodialysis patients and showed that those he-
J or U curve effect has been observed in which those modialysis patients who had greater weight-for-height
individuals with a low BMI also demonstrated an in- percentiles had lower mortality rates.
creased mortality, although not as high as obese individu- The prospective Dialysis Outcomes and Practice Pat-
als [16, 17, 19]. terns Study (DOPPS) [26, 27] has allowed comparison
Hemodialysis patients have lower BMI values as com- of BMI-mortality relationships in the United States and
pared with age- and sex-matched controls from the gen- Europe and among a variety of “healthier,” as compared
eral population [1, 3]. A lower BMI is consistently found with “sicker” hemodialysis patient subgroups, such as
to be a strong predictor of an elevated mortality risk younger patients, never-smokers, and those with less
[20–22] (Fig. 1). In contrast, a higher BMI, either mild chronic illnesses. The DOPPS study provided baseline
to moderate overweight or obesity, has generally not demographic, comorbidity, and BMI data on 9714 hemo-
dialysis patients in the United States and Europe frombeen associated with any increase in mortality risk, ex-
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Fig. 2. Relative mortality risk versus body mass index (BMI) in hemo-
dialysis patients: United States and Europe (DOPPS Study). (A ) Mor-
tality risk decreases as BMI increases. An inverse linear relationship
between mortality and ln (BMI) is significant for both the United States
and Europe (P  0.0001). Adjusted for demographics, all comorbid
conditions and albumin. Reprinted with permission from Leavey et al,
Nephrol Dial Transplant 16:2386–2394, 2001 [26]. (B ) Relative mortality
risk versus BMI for sicker and healthier hemodialysis patients. Tertiles
of a linear indicator of severity of illness define the three cohorts. In
each cohort mortality risk was highest for BMI  20 and lowest for
BMI  or  30 (Inverse linear relationship with lane (BMI), P 
0.0001). Reprinted with permission from Leavey et al, Nephrol Dial
Transplant 16:2386–2394, 2001 [26].
1996 to 2000. Relative mortality risk decreased with in- lower survival rate in patients with lower lean body mass.
For those with an initial lean body mass 73%, 63% tocreasing BMI. A BMI20 kg/m2 was consistently associ-
ated with the highest relative mortality risk. Overall, a 73%, and 63%, the 2-year survival probabilities were
88.3%, 81.2%, and 65.2%, respectively. Johnson et al [31]lower relative risk (RR) of mortality as compared with
a BMI of 23 to 24.9 kg/m2, was found for overweight studied the BMI in a limited number of peritoneal dial-
ysis patients and found that obesity conferred a signifi-(BMI 25 to 29.9 kg/m2; RR 0.84; P  0.008), for mild
obesity (BMI 30 to 34.9 kg/m2; RR 0.73; P  0.0003), cant survival advantage in the peritoneal dialysis popula-
tion. Chung, Lindholm, and Lee [32] performed a similarand for moderate obesity (BMI 35 to 39.9 kg/m2; RR
0.76; P  0.02) (Fig. 2A). Most intriguingly, subanalysis study in Korean peritoneal dialysis patients and found
that lean body mass was an independent predictor ofof categories of patients defined by overall health status
at the beginning of the study and indicated by severity death in peritoneal dialysis patients.
There are very few studies that have shown a deleteri-of illness tertiles were performed and resulted in similar
associations (Fig. 2B), contrary to the initial hypothesis ous effect of a high BMI in ESRD patients. These are
usually based on small sample sizes or different sub-of the investigators that reverse epidemiology may not
exist in healthier or younger ESRD patients. There was groups of dialysis patients. For instance, Kaizu et al [33]
studied 116 nondiabetic hemodialysis patients and useda survival benefit for healthy overweight patients (BMI
25 to 29.9 kg/m2) that was even greater for the obese Kaplan-Meier survival analysis and proportional hazard
models to calculate the RR of mortality in BMI quintiles.patients (BMI30 kg/m2), and this was observed for the
healthier as well as the sicker groups of hemodialysis- They showed that patients with BMI of less than 16.9
kg/m2 and higher than 23.0 kg/m2 showed lowered sur-treated patients. Even within a cohort of patients younger
than 45 years old with low comorbidity, overweight/obe- vival relative to the patients with BMI of 17.0 to 18.9
kg/m2. However, even in this study, patients with a BMIsity was not associated with decreased survival [26, 27].
Finally, a similar inverse weight-mortality relationship 16.9 kg/m2 were shown to have the highest risk of
mortality independent of other factors.has been reported among chronic peritoneal dialysis pa-
tients. In the CANUSA study, a 1% difference in percent Although high BMI has been emphasized as a strong
risk factor for morbidity and mortality in the generallean body mass was associated with a 3% change in the RR
of death [28, 29]. McCusker et al [30] found a significantly population, a recent study suggests that a higher BMI
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in certain age groups in normal or nonuremic individuals
may not necessarily be associated with higher morbidity
and mortality [11]. Similar to ESRD patients, Grabowski
and Ellis [34] showed that a high BMI does not predict
mortality in older people. In their Longitudinal Study
of Aging that examined 7527 participants 70 years old
and older, they demonstrated reduced mortality in obese
older people and showed that thin older people remained
more likely to die than normal older people. A similar
finding from Italy showed that a low BMI was a signifi-
cant and independent predictor of shortened survival in
hospitalized patients [12].
Blood pressure: Is hypertension protective?
The role of hypertension as a risk factor for increased
Fig. 3. Relative risk (RR) of death according to predialysis systoliccardiovascular or cerebrovascular events in the general
blood pressure compared with the reference group of 120 to 149 mm Hgpopulation is indisputable [35–37]. Even high normal
(RR  1.00). Three separate models are shown according to the level
blood pressure confers a significantly greater risk of cu- of statistical adjustment. *P  0.0001. Reprinted with permission from
Port FK et al, Am J Kidney Dis 3:507–517, 1999 [51].mulative incidence of cardiovascular events [37]. Similar
to the general population, several studies have also sug-
gested that hypertension in dialysis patients is associated
with increased mortality risk [38, 39], including the French
its impact on dialysis outcome and on cardiovascularTassin data on long-duration hemodialysis [40, 41]. This
mortality has been underappreciated. Iseki et al [49]has led several advisors to focus on predialysis blood
showed a strong association between low diastolic bloodpressure (e.g., systolic blood pressure 160 mm Hg) as
pressure and risk of death in a cohort of 1243 hemodialy-an indicator of quality of care by hemodialysis units [39].
sis patients who were followed up for 5 years. In thisHowever, although hypertension in ESRD traditionally
study, the death rate was inversely correlated with dia-has been poorly controlled [42, 43], elevated blood pres-
stolic blood pressure, which per se showed a significantsure may not represent the primary risk for overall sur-
positive correlation with serum albumin and a negativevival in dialysis patients [44–46]. Tassin data showing
correlation with age. Zager et al [47], in a study of moreimproved dialysis survival with blood pressure control
than 5000 hemodialysis patients followed up for a mean[40, 41] may be confounded by other survival advantages
of 2.9 years, noted that the relative death rate for patientssince the patients treated with 6-hour, three times a week
with predialysis or postdialysis hypotension (systolic blooddialysis are reported not to be volume expanded; hence,
pressure 110 mm Hg) increased to four times normalit can be argued that low blood pressure in these individ-
or greater than 2.5 times normal, respectively. Port et aluals is less likely to indicate cardiac pump failure and
[51] analyzed data from 4839 hemodialysis patients inmore likely to reflect a desirable homodynamic state.
the Case Mix Adequacy Study of the United States RenalIndeed, several recent studies, including those based on
Data System (USRDS) and found that when predialysislarge sample sizes, failed to find that high blood pressure
systolic blood pressure decreased below the referenceis an independent mortality risk factor [47, 48]. Findings
group (120 to 149 mm Hg), the relative mortality riskpresented by Lowrie et al [48], Duranti, Imperiali, and
increased and reached statistically significant values atSasdelli [44], Zager et al [47], and Iseki et al [49] from
pressure measurements less than 110 mm Hg (Fig. 3).studies of large hemodialysis populations indicated sur-
Fleischmann, Bower, and Salahudeen [8] found that theprisingly little or no risk associated with systolic hyper-
cumulative hazard for dying was significantly influencedtension. In a cross-sectional study of 936 hemodialysis
by the predialysis mean arterial pressure tertiles, with thepatients in the HEMO Study, Cheung et al [50] reported
lowest survival in the lowest third and the best survival inno significant linear or nonlinear association between
the upper third. A correlation of low predialysis systolicpredialysis systolic blood pressure and any of the cardio-
blood presssure with increased mortality has also beenvascular disease end points.
reported by Lowrie et al [48] and Duranti, Imperiali,While contemporary thinking reiterates the link be-
and Sasdelli [44].tween hypertension and cardiovascular morbidity and
The concept of a U-shaped curve linking increasedmortality in the general population [35–37], recent stud-
mortality to low blood pressure was previously reportedies of ESRD patients point to a link between low blood
in a non-ESRD population by Cruickshank, Thorpe, andpressure and poor survival. Even though the adverse
consequences of low blood pressure is not a new concept, Zacharias [52] when they examined outcomes in the gen-
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eral population undergoing antihypertensive treatment.
Historically, hypertension is associated with concentric
left ventricular hypertrophy (LVH), ventricular dilata-
tion, ischemic heart disease, and congestive heart failure.
However, after the development of cardiac failure, low
blood pressure or hypotension predicts mortality and is
a potential marker for severity of cardiac disease [38, 53].
In addition, patients presenting with baseline predialysis
hypotension may possess such subclinically significant
risk factors or comorbidities such as hypoalbuminemia,
heart failure, and ischemic cardiomyopathy [49, 54]. Low
blood pressure may be a reflection of autonomic neurop-
athy that, in turn, is a marker for more severe uremic
complications. Because antihypertensive drug therapy
may contribute to low predialysis systolic blood pressure,
Fig. 4. Relative risk (RR) of death in hemodialysis patients accordingone may hypothesize that either overmedication (per-
to serum cholesterol concentration compared to the reference group
haps specific antihypertensive agents) or cardiac pump (cholesterol 200 to 250 mg/dL, RR1.00). Reprinted with permission
from Lowrie EG and Lew NL, Am J Kidney Dis 15:458-482, 1990 [5].failure are the major contributors to the observed associ-
ations. To date, no study has examined the potential
role of medication as a cause of low blood pressure
and increased mortality in dialysis patients. Ongoing and
indicated an opposite direction of the serum cholesterol–future studies might address these issues.
mortality relationship, consistent with that seen in the
general population. For example, a retrospective studySerum cholesterol: Is hypercholesterolemia protective?
of a cohort of 190 peritoneal patients with an averageIn the general population, hypercholesterolemia is a
follow-up of 12 months and based on Cox model showedknown risk factor for cardiovascular morbidity and mor-
that an elevated serum cholesterol level was associatedtality [55–57]. Among lipid components, increased serum
with increased mortality [61]. Nevertheless, this samelevels of low-density liproprotein (LDL) and non-high-
study showed that a low serum creatinine concentrationdensity lipoprotein (HDL) cholesterol appear to have
also predicted mortality (see below).the strongest predictive value for poor cardiovascular
Similar findings regarding the association of low serumoutcome, whereas HDL-cholesterol is generally consid-
cholesterol and poor outcome have been reported forered protective in the general population [57].
elderly persons who do not have ESRD [62–64]. ForIn the Diaphane Collaborative Study Group, Degoulet
instance, Volpato et al [63] investigated the relationshipet al [23] reported that a lower plasma total cholesterol
between low cholesterol and mortality in older personslevel was associated with a significantly higher risk of death
in a prospective cohort consisting of 4128 elderly patientsfrom cardiovascular disease in a cohort of 1453 French
with a mean age of 78.7 years and a median follow-uphemodialysis patients. Lowrie and Lew [5] analyzed a
period of 4.9 years. They found that in those with a lowgroup of more than 12,000 prevalent hemodialysis pa-
serum cholesterol level, defined as160 mg/dL, all-causetients and found that serum cholesterol level was in-
mortality was significantly higher than those with normalversely correlated with the risk for death in a multivariate
or high serum cholesterol concentrations. Krumholz et allogistic regression adjusting for several case-mix factors
[64] failed to show any significant association betweenand biochemical parameters (Fig. 4). Avram et al [58]
hypercholesterolemia or low HDL-cholesterol and all-showed that serum cholesterol concentration was ele-
cause mortality, coronary heart disease mortality, or hos-vated in the long-term dialysis survivors. Fleischmann,
pitalization for myocardial infarction or unstable anginaBower, and Salahudeen [8] studied 453 hemodialysis pa-
in a cohort of persons older than 70 years.tients prospectively and showed that among lipids, the
second and third tertiles of total cholesterol as well as
Serum creatinine: Is high better than low?LDL and HDL cholesterol were associated with better
In the general population, a slight or moderate in-survival, although this was only a trend that was not
crease in serum creatinine has been shown to be an inde-statistically significant. More recently, Iseki et al [59]
pendent risk factor of cardiovascular disease [65–67]. Areported similar findings based on a sample of 1167 he-
secondary analysis of the HOPE Study showed that inmodialysis patients who were followed for up to 10 years.
patients who had either preexisting vascular disease orWe showed similar findings in a small cohort of hemodi-
diabetes mellitus and an additional cardiovascular riskalysis patients who were followed for up to 12 months
[60]. Of note, some less recent studies in ESRD patients factor, the presence of mild renal insufficiency signifi-
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cantly increased the risk for subsequent cardiovascular between the fasting plasma tHcys level and the prevalence
of cardiovascular disese in dialysis patients, using crudeevents [65]. The HOT Study showed that a baseline
elevation in serum creatinine is powerful predictors of or multiple logistic regression analyses adjusted for other
risk factors [80]. More recently Suliman et al [81, 82]cardiovascular events and death [66].
In dialysis patients, the serum creatinine, a reflection found that among 117 hemodialyis patients, those with
cardiovascular disease (60%) had significantly lower tHcysof muscle mass or meat ingestion and/or the degree of
dialysis efficiency, has also been shown to be a predictor of levels than those without cardiovascular disease, although
both groups still had higher plasma tHcys levels thanmortality but in the opposite direction (i.e., those dialysis
patients with a higher serum creatinine live longer). This is the general population. Wrone et al[83] performed a cross-
sectional analysis of 459 dialysis patients, and showedcontrary to the notion that well-dialyzed dialysis patients
with higher Kt/V should have lower serum creatinine that those with a history of cardiovascular disease had
lower levels of predialysis plasma tHcys than those with-concentrations compared to those in whom dialysis treat-
ment is not adequate. Lowrie and Lew [5] found that out a history of cardiovascular disease. This negative rela-
tionship persisted in multivariate analyses when control-the serum creatinine level was inversely correlated with
the risk for death. Avram et al [58] found that the enroll- ling for predictors of cardiovascular disease, such as age,
gender, and BMI. Mean plasma tHcys was higher inment serum creatinine was significantly higher among
long- and very long-term hemodialysis and peritoneal patients without a history of cardiovascular disease than
in those with cardiovascular disease [83]. Of note, bothsurvivors. In the study by Tattersall, Greenwood, and
Farrington [68], there was no significant change in the of the above-mentioned studies found a statistically sig-
nificant, positive correlation between predialysis plasmapredialysis serum creatinine values for hemodialysis pa-
tients from the time they initiated dialysis as compared tHcys and albumin concentration, which is a known,
strong predictor of mortality in dialysis patients. We havewith their values 6 months later. These results suggest
that the factors that link lower predialysis serum creati- recently found a similar positive correlation in a sample
of 368 hemodialysis patients, which may indicate thatnine values to increased mortality in dialysis patients may
be determined when the patients commence renal replace- plasma tHcys is a nutritional and/or inflammatory marker
in dialysis patients (abstract; Kalantar-Zadeh et al, Amment therapy. In the 1992 USRDS Annual Report, the
investigators analyzed hemodialysis patients initiating Soc Nephrol, 13:222A, 2002). It is noteworthy that stud-
ies showing the inverse relationship in dialysis patientsdialysis in 1986 and 1987 and found that increasing serum
creatinine level was associated with decreasing mortality are all of recent origin. One reason why similar results
had not been reported in the past may be related to[69]. Fink et al [70] studied 5388 incident hemodialysis
patients followed up for almost 2 years and found that publication bias that will be discussed later in this manu-
script (see below).serum creatinine level was inversely correlated with mor-
tality risk. Among studies of peritoneal dialysis patients, However, these observations do not necessarily ex-
clude the role of hyperhomocysteinemia as a risk factora retrospective study of a cohort of 190 peritoneal pa-
tients with an average follow-up of 12 months and based for poor ESRD outcome, since other factors might be
present that confound the relationship between tHcyson the Cox model found that a low serum creatinine
was an independent variable significantly associated with levels and cardiovascular disease. Of particular impor-
tance is the fact that even studies that found a reverseincreased risk of death [71].
epidemiology confirmed that tHcys was higher in dialysis
Plasma homocysteine: Is high better than low? patients as compared to the general population [82, 83].
Assuming that an increase in tHcys level carries an inde-Plasma total homocysteine (tHcys) has been estab-
lished as a new risk factor for increased cardiovascular pendent risk of cardiovascular, this may imply that al-
most all dialysis patients are already exposed to thismorbidity and mortality in the general population [72, 73].
Estimated survival among non-ESRD patients with coro- risk. Thus, the apparently paradoxic association between
tHcys and cardiovascular disease does not strictly conflictnary artery disease can be stratified according to plasma
total homocysteine levels. Higher homocysteine levels with the thesis that hyperhomocysteinemia is a risk factor
for cardiovascular disease. However, within this popula-are associated with a worse outcome [72]. A similar asso-
ciation as in the general population was found in some tion, those with the highest tHcys level may have some
survival advantages due to better nutrition.studies of dialysis patients (i.e., a higher plasma tHcys
was found to be associated with increased risk of cardio-
Other possible examples of reverse epidemiologyvascular disease) [74–79].
However, conflicting findings have been reported re- Excess parathyroid hormone (PTH) has long been con-
sidered detrimental to the health of patients, includinggarding the association between the plasma tHcys level
and the prevalence of cardiovascular disease in chronic those with ESRD [84]. PTH has been implicated as a
multisystem uremic toxin, and hyperparathyroidism canrenal failure patients. Bostom et al found no relationship
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be a debilitating complication in dialysis patients [84]. homocysteine are established risk factors for ischemic
heart disease in the general population. The paradoxHyperphosphatemia that is closely related to hyperpara-
thyroidism is associated with increased mortality in dial- becomes even more paramount when it is recognized
that it is not a question of the existence or lack of anysis patients [85]. Avram et al [86] studied prospectively
the relationship between the enrollment serum intact association between these risk factors and the clinical
outcomes, but often the complete reversal and indeedPTH and all-cause mortality in 345 hemodialysis and 277
peritoneal dialysis patients for 14 years and found that the opposite direction of this relationship. Hence, there
must be prevailing conditions that are characteristicallylower than expected levels of PTH in uremic patients
are associated with increased mortality. Moreover, Guh present in dialysis patients that render them more sus-
ceptible to a poor outcome when low body mass, lowet al [87] recently reported similar findings that low levels
of serum PTH at entry and lower time-dependent PTH blood pressure, or decreased serum values of cholesterol,
creatinine, and homocysteine are present. Several sug-levels predict mortality in hemodialysis patients. Avram
et al [86] hypothesized that inadequate protein intake, gested explanations are offered for this inverse associa-
tion. Survival bias, time discrepancies among competingphosphorus intake or both result in impaired develop-
ment of the expected secondary hyperparathyroidism risk factors, the MICS, and several other hypotheses are
presented as possible causes.and in the excess mortality risk inherent with malnutri-
tion. However, to date epidemiologic studies have shown
Survival biasa positive association between a high serum phosphorus
and poor outcome among ESRD patients [85, 86]. Hence, Since dialysis patients have undergone specific pro-
cesses of selection and survival, their characteristics maythe association between serum PTH and outcome in dial-
ysis patients may be unrelated to serum phosphorus and not be similar to the general population. Therefore, the
relationship between the risk factors and outcomes maymay reflect other aspects of nutritional status.
Another example is serum ferritin and its association have been modified. According to an analysis based on
the National Health and Nutrition Examination Surveywith anemia. In the general population, a low serum ferri-
[96], in the United States there are over 10 to 20 milliontin is a marker of iron deficiency and anemia that may
patients with chronic kidney disease (CKD) and an ele-not respond to erythropoietin unless iron is repleted [88].
vated serum creatinine due to a chronic, irreversible andHowever, in ESRD patients, a high and not a low serum
probably progressive damage to the kidney. However,ferritin is associated with a more severe and refractory
according to the USRDS data [1], the number of peopleanemia [89, 90]. This may be due to hyporesponsiveness
with ESRD is approximately 400,000 at this time and isto erythropoietin, which can occur in the setting of the
projected to increase to almost 650,000 by the year 2010.malnutrition-inflammation complex syndrome (MICS)
This constitutes only a small fraction (less than 5%) ofin dialysis patients [60], especially since ferritin is an
the large pool of CKD patients in the United States.acute phase reactant [89, 90].
Current thinking suggests that a large population of CKDFinally, another possible example of risk factor rever-
patients will not live long enough to develop ESRD andsal is the association between the amount of energy (calo-
commence maintenance dialysis. One explanation forrie) or food intake and mortality. In the general popula-
this phenomenon is that CKD patients have a high mor-tion, an increased energy intake may be associated with
tality rate since many of them have severe and complexincreased BMI and hypercholesterolemia and, hence, with
comorbid conditions, such as diabetes mellitus, hyper-a higher mortality rate and risk of cardiovascular disease
tension, and atherosclerotic vascular disease. Moreover,[91, 92]. In contrast, in dialysis patients increased protein
renal disease with proteinuria or an increased serum creat-intake, estimated from the urea generation and urea
inine by itself is an independent risk factor for greaterkinetics, may lead to an improved nutritional status, re-
morbidity and mortality, particularly from atheroscle-flected by an increased albumin level, and a better sur-
rotic heart and cerebrovascular diseases [65, 66]. Thus,vival [93–95]. However, data in dialysis patients are
many CKD patients do not reach ESRD due to theirmostly based on indirect measurements of protein intake
high mortality. This can explain why only a small propor-and studies concerning the possible association between
tion of CKD patients develop ESRD. It is not clear whatenergy (calorie) intake and dialysis outcomes are yet to
specific characteristics of this relatively small percentagebe developed.
of CKD patients give them a greater survival chance to
reach ESRD status. An alternative explanation, how-
POSSIBLE EXPLANATIONS FOR ever, is that those CKD patients who develop ESRD
REVERSE EPIDEMIOLOGY simply have a more accelerated rate of progression of
The concept of reverse epidemiology appears at first their chronic renal failure. But whatever the survival
to be confusing, especially because hypertension, obe- features are, these “unfortunately lucky” individuals may
be considered as “specifically selected” people, who aresity, and high levels of serum cholesterol, creatinine, and
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not necessarily genetically or phenotypically similar to patients have a mortality risk that is greater than the
general population [2], the long-term effects of these risktheir CKD predecessors and may not have the survival
characteristics and epidemiologic features of their pro- factors on future mortality may be overwhelmed by the
short-term effects of other factors on dialysis mortality.genitors. Some of those who have survived to comprise
the ESRD population might be “exceptional individu- Indeed, it may be difficult, if not impossible, to observe
a significantly greater life expectancy with reduction ofals” who successfully survived the conventional (tradi-
tional) risk factors, which are often present strongly in the traditional risk factors in dialysis patients who have
a short life expectancy, even when such a risk factorCKD patients. Hence, the assumption that the epidemi-
ology of cardiovascular risk factors is the same in ESRD reduction is beneficial in the general population who
have a normal life expectancy.individuals as in the general population may be flawed,
because a survival bias, a form of selection bias, may An example of this time discrepancy in non-ESRD
populations may concern obesity and underweight. Inheavily influence the epidemiologic constellations in this
small proportion of CKD survivors (i.e., the dialysis pa- the general population in the United States, as well as
in most industrialized countries, manifestations of over-tients). A similar trend is observed in elderly individuals,
who have reached advanced age possibly due to survival nutrition such as overweight/obesity and hypercholester-
olemia are major risk factors for cardiovascular mortalityadvantages, and they also are reported to have a different
epidemiology with different cardiovascular disease risk [15–19, 56, 57]. These are also countries where people
have a greater life expectancy compared to individualsfactors than the general population [11, 13, 34].
It should be noted that many epidemiologic studies in in other parts of the world. Studies of risk factors of
cardiovascular mortality are essentially based on theseESRD patients are based on a mixed pool of incident and
prevalent dialysis patients (i.e., those who have started populations. In contrast, in developing countries, which
represent the majority of the world’s population, under-dialysis recently and those who have been on dialysis
for a number of years are treated equally in such studies). nutrition is still a powerful determinant of poor clinical
outcome and morbidity and mortality, leading to aThis may lead to what epidemiologists call “incidence-
prevalence” or “survival” bias, which per se is a form of shorter life expectancy [99–101]. A hypothetical demon-
stration of the combined effect of competitive risk factorsselection bias [97]. In other words, those incident patients
who had more risk factors or were more vulnerable to (over- versus under-nutrition) is presented in Figure 5.
Thus, in dialysis patients who have a short life expec-such risks did not survive long enough to be included in
a cross-sectional study that encompasses many prevalent tancy, any factor that may improve short-term survival,
such as high blood pressure, obesity, and hypercholester-patients who have been on dialysis for a number of years
and who hence over-represent ESRD patients who have olemia may exert a desirable effect on longevity, whereas
conditions that are traditionally associated with long-exceptional survival advantages. Indeed, the majority
of incident dialysis patients die, especially due to the term survival such as rigorous blood pressure control,
low body weight-for-height, and low serum cholesterolexceptionally high ESRD mortality rate, currently ap-
proximately 20% in the United States [1]. Hence, even and homocysteine, may be less relevant. Such factors
may even be harmful if they cause, represent, or aggra-longitudinal studies that are based on a mixture of inci-
dent and prevalent dialysis patients may be heavily in- vate states of under-nutrition, hypotension or cardiac
failure.fluenced by a survival bias [98]. Survival bias can poten-
tially exert a strong influence on both epidemiologic
Malnutrition inflammation complex syndrome (MICS)studies and clinical trials, especially when patients who
have varying degrees of duration of dialysis are enrolled Measures of protein-energy malnutrition (PEM) and
inflammation are major predictors of clinical outcometogether [97, 98]. In this regard, it is possible that the
concept of reverse epidemiology is a consequence of in dialysis patients [3–5, 7, 9]. Dialysis patients with car-
diovascular disease have a higher prevalence of malnutri-systematic errors in epidemiologic data analysis [83].
However, some epidemiologic data based exclusively on tion and hypoalbuminemia and a lower protein intake
than those without cardiovascular disease [7, 102]. Sev-incident dialysis patients still show the same risk factor
reversal [25], indicating that this phenomenon cannot be eral studies report strong relationships between hypo-
albuminemia and cardiovascular disease in dialysis pa-solely explained by survival bias.
tients and suggest that hypoalbuminemia is an important
Time discrepancies among competitive risk factors risk factor for cardiovascular disease in these individuals
[54, 103–105]. Cardiac diseases such as heart failure maySurvival advantages that exist in obese, hypertensive,
hypercholesterolemic, hypercreatininemic, or hyperho- engender anorexia and, if sufficiently severe, may inde-
pendently induce muscle wasting, which is also known asmocysteinemic dialysis patients may, in the short-term,
outweigh the harmful effects of these risk factors on cardiac cachexia [102, 106]. However, it is not completely
clear how cardiac disease, inflammation, hypoalbumi-cardiovascular disease in the long-term. Since dialysis
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Fig. 5. A hypothetical representation of com-
bining two competing risk factors with time
discrepancy. (A ) A low serum cholesterol in
the setting of under-nutrition is a short-term
marker of mortality (1-year scale). (B ) A high
serum cholesterol in the setting of over-nutri-
tion leads to an increased mortality rate over
a long-term interval (10-year scale). (C ) After
combing both impacts, the short-term risk fac-
tor pattern (under-nutrition associated hypo-
cholesterolemia) predominates.
nemia, and other measures of PEM in dialysis patients with reduced renal function or other proinflammatory
conditions in dialysis patients. Frequent contact with di-are interrelated [106, 107]. It has been postulated that
the common link among these conditions is inflammation alysis membranes, vascular access grafts or catheters or
dialysate, or peritoneal dialysis fluid may each constitute[7, 54, 103, 104, 106, 108]. A common mechanism for
the development of cardiovascular disease and PEM in a proinflammatory condition [7, 109]. Increased release
or activation of inflammatory cytokines, such as interleu-dialysis patients may be cytokine activation associated
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kin-6 (IL-6) or tumor necrosis factor- (TNF-), may shown to be dependent on nutritional status, protein
suppress appetite, cause muscle proteolysis and hypo- intake, and serum albumin in hemodialysis patients. He-
albuminemia, and may be involved in the processes that modialysis patients with cardiovascular disease had lower
lead to atherosclerosis [66, 104, 110]. Nevertheless, the tHcys levels as well as a higher prevalence of malnutri-
degree to which PEM in dialysis patients is caused by tion and hypoalbuminemia than those without cardiovas-
inflammation is not clear [7, 110]. Some studies suggest cular disease. Furthermore, in another study plasma
that PEM and inflammation each independently contrib- tHcys was shown to rise during treatment of malnour-
ute to hypoalbuminemia and subsequently increase mor- ished peritoneal dialysis patients with an amino acid–
bidity and mortality [105]. Since both PEM and inflam- containing peritoneal dialysate (1.7 g methionine/day)
mation are strongly associated with each other and can [115]. The presence of MICS may further reinforce this
change many nutritional measures in the same direction, relationship by suppressing serum albumin, which is an
and because the relative contributions of measures of important carrier protein for plasma tHcys [81, 82, 106].
these two conditions to each other and to outcomes in The puzzling inverse relationship between a low blood
dialysis patients are not yet well defined, MICS has been pressure and poor outcome in the dialysis population
suggested to denote the important contribution of both might also be accounted for by nutritional status and/or
of these conditions to ESRD outcome [7, 60]. Some inflammation. Iseki et al [49] showed a significant associ-
investigators have used other terminologies such as “mal- ation between a low diastolic blood presssure, hypoalbu-
nutrition inflammation atherosclerosis” (MIA) to em- minemia, and risk of death in a cohort of hemodialysis
phasize the importance of atherosclerosis as the conse- patients. They analyzed the causes of death with regard
quence of MICS [54, 110]. Furthermore, oxidative stress to the relationship between serum albumin and blood
may play an important integral part in the associations pressure in 1243 hemodialysis patients who were fol-
between inflammation, malnutrition and atherosclerosis, lowed for up to 5 years. The death rate was inversely
since variations of serum albumin may be correlated not correlated with diastolic blood pressure, which per se was
only with outcome but also with inflammation, cardiovas- positively correlated with serum albumin and negatively
cular disease, and serum cholesterol and tHcys concen- correlated with age. Hence, hypotension may in some
trations [111, 112]. No matter what it is called or caused cases be a manifestation of MICS in hemodialysis patients.
by, the theory of reverse epidemiology in ESRD is com-
patible with the existence of MICS or MIA and its inter- Other hypotheses
play with the traditional risk factors. Goldberg, Tindira, and Harter [116] suggest that the
The existence of paradoxic risk factors could be accen-
paradigm of coronary artery disease in ESRD shifts from
tuated by the MICS, possibly in several ways. First, pa-
solely traditional risk factors, such as age, diabetes, hy-tients who are underweight or who have a low serum
perlipidemia, and hypertension, to a number of addi-cholesterol, creatinine, or homocysteine, may be suffer-
tional factors that may regulate coronary event rates ining from the MICS and its poor outcome. Thus, MICS
a different way in uremia. Theoretically, hypotensionmay both cause these alterations and also be associated
and under-nutrition can contribute to the increased rela-with increased mortality either caused by the illnesses
tive risk of death by several mechanisms, such as acutethat engender the MICS or the cardiovascular disease
coronary syndrome, autoregulation dysfunction, isch-that seems to be promoted by the MICS [106, 113, 114].
emia, and arrhythmiagenecity [117, 118]. These factors,Second, the above paradoxic factors may indicate a state
if indeed altered or exaggerated in uremic milieu, mayof under-nutrition, which may predispose to infection or
provide an environment in dialysis patients, in whomother inflammatory processes [7]. Finally, it has been
hypotension and undernutrition may become more in-argued that when individuals are malnourished, they are
fluential than the traditional risk factors in the develop-more susceptible to the ravages of inflammatory diseases
ment of cardiovascular disese.[113]. Hence, any condition that potentially attenuates
Chronic inflammatory processes may independentlythe magnitude of PEM or inflammation should be favor-
predispose to both malnutrition and atherosclerosis. IL-6able to dialysis patients. This notion can explain why
predicts hypocholesterolemia [119], malnutrition [120,there is a reverse epidemiology of cardiovascular risk
121], and atherosclerosis [122, 123] in dialysis patients.factors in dialysis patients, especially since almost all
Inflammation can indeed lead to hypocholesterolemiathe so-called nontraditional protective factors, such as
in ESRD patients [59, 119]. Moreover, chronic infusionobesity, hypercholesterolemia, hypercreatininemia, and
of IL-1 or TNF- (cachectin) has been shown to causehyperhomocysteinemia, are related to nutritional status.
anorexia, rapid weight loss, and a decline in body proteinSuliman et al [81, 82] have reported a more specific
stores [124]. Hence, given the fact that inflammation isexample of the contribution of the MICS to risk factor
more common in ESRD patients as compared to thereversal concerning with hyperhomocysteinemia in dial-
ysis patients. In their study, plasma tHcys levels were general population [104, 120], inflammation by itself may
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precede under-nutrition and lead to the risk factor rever- with inversed association may be to consider them erro-
neous or flawed and hence be reluctant to report themsals in individuals with ESRD.
There may be other confounding factors that may ex- [131]. However, as more reports indicative of reverse epi-
demiology in ESRD have been published recently, moreplain some of the risk factor reversals in dialysis patients.
Both low body mass and low blood pressure may be investigators may be encouraged to report their similar
findings. This may explain why more frequent reportsconsequences of cigarette smoking [125, 126] and/or con-
gestive heart failure [102, 106], conditions that are associ- and publications consistent with the reverse epidemiol-
ogy have emerged only recently.ated with increased ESRD mortality. These conditions
may also be associated with an increased prevalence of It is important to appreciate that some of the discussed
risk factors may represent different biologic or medicalinflammation and malnutrition [127, 128]. Heart failure
may engender anorexia and may independently induce phenomena in ESRD patients as compared to the gen-
eral population. Serum creatinine, for instance, is a re-cachexia [106]. A low blood pressure, a potential indica-
tor of severe heart disease, is thus associated with poor flection of renal function in the general population,
whereas it is essentially representative of skeletal muscleoutcome [53]. Moreover, a low blood pressure may be
caused by autonomic neuropathy that, in turn, can be mass and/or meat ingestion as well as the dose of dialysis
in ESRD patients. Similarly, a pre-dialysis blood pres-the result of uremic toxicity or the ravages of diabetes
[129]. Hence, it may not be normo- or hypotension per sure measurement may represent a different underlying
disease processes in hemodialysis patients who are oftense that is detrimental but rather the underlying cause of
low blood pressure (i.e., cardiac pump failure and/or volume overloaded. Thus, a low predialysis blood pres-
sure in patients who are likely to be volume expandedautonomic neuropathy).
Finally, a less well-substantiated hypothesis represents is more probably due to a sick heart, whereas in the
general population it may more likely indicate excellentthe notion that what we consider as reverse epidemiology
(the stronger impact of under nutrition) may indeed be circulatory homodynamics. Hence, the etiology of “re-
verse epidemiology” in dialysis patients may be quitethe natural epidemiology in human and that the so-called
different for various risk factors, and the term “reverseconventional epidemiology (over-nutrition) is a new and
epidemiology” may be a misnomer. Nevertheless, it isunusual phenomenon in human history [130]. In recent
important to first exhaust the possibility of a single unify-decades, excess weight and obesity have become mass
ing entity to be accounted for all or most of the above-phenomena with a pronounced upward trend in most
mentioned risk factor reversals. We believe that PEMindustrialized nations. However, despite the detrimental
and inflammation (MICS) are the best candidates.effects of being overweight, these populations indeed live
Despite all these concerns, the evidence is strong thatlonger than ever. Moreover, with aging, the detrimental
a risk factor paradox indeed exits in those who reacheffects of obesity, over-nutrition, and hypertension may
ESRD and who continue to have an unacceptably highdiminish if not disappear, a similar trend that can be
rate of mortality, currently approximately 20% in theobserved in ESRD population as well.
United States. This high mortality rate has not substan-
tially been changed in the recent years despite aggressive
CONCLUSION efforts toward an optimal management of traditional risk
The reversal of certain key risk factors in dialysis pa- factors in these individuals. Hence, it is important to
tients poses serious questions. Is the increasing preva- explore the causes of reverse epidemiology and to ascer-
lence of obesity and its detrimental impact to health tain how best to reverse these associations in dialysis
in the general population of any relevance in dialysis patients. We believe that in dialysis patients more atten-
patients? Do overnutrition, obesity, hypertension, or hy- tion should be focused on optimal management of under-
percholesterolemia that promote atherosclerosis and nutrition and inflammation based on the mechanisms
mortality in the general population prevent poor out- responsible for the reverse epidemiology. However, pre-
come in dialysis patients, and if so how? Should dialysis mature or radical conclusions to discontinue antihyper-
patients be advised to increase their nutrient intake in tensive or antihyperlipidemic treatment should be avoided
order to gain weight and to increase their serum choles- until such information is forthcoming. For instance, the
terol, creatinine, and homocysteine levels? Should their antihypercholesterolemic agent, 3-hydroxy-3-methylglu-
target blood pressure be higher? Can these reversed taryl coenzyme A (HMG-CoA) reductase inhibitor or
relationships be used to establish therapeutic goals? such antihypertensive agents as angiotensin-converting
Publication bias may have handicapped or delayed enzyme inhibitors may have an anti-inflammatory effect,
reporting such paradoxical findings in dialysis patients which can be beneficial in the management of the ele-
as the association between plasma homocysteine and ments of MICS and improved outcome in dialysis pa-
cardiovascular disease in dialysis patients, since the in- tients irrespective of the existence of reverse epidemiol-
ogy [132–135]. It is also important to appreciate thatvestigators’ first impression upon encountering results
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